The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory ...

Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant ...

Hazards of the LA wildfires necessitate awareness that first responders and those central to the fires may be at risk for ...

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with ...

Key opinion leaders explore approaches to dose modifications or treatment pauses due to side effects, including examples ...

One of the hardest lessons learned occurred after I inadvertently failed at communication and education before transferring a ...

Staying up to date with data from trials and information from organizations dedicated to cancer research is crucial for oncology nurses and APPs.

Patients who receive certain cancer treatments are at greater risk of secondary malignancies and must be educated accordingly ...

How do you manage gastrointestinal side effects in patients on lorlatinib? Do you provide any preventive tips, and how does this compare to managing GI side effects from other ALK inhibitors?